Sergey Tjulandin
Overview
Explore the profile of Sergey Tjulandin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
692
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Emelyanova M, Pudova E, Khomich D, Krasnov G, Popova A, Abramov I, et al.
Ther Adv Med Oncol
. 2022 Mar;
14:17588359221083050.
PMID: 35309086
Background: Mutations in homologous recombination (HR) and Fanconi anemia (FA) genes may predispose to pancreatic cancer (PC) and enable the prediction of sensitivity to platinum-based chemotherapy. FOLFIRINOX is a standard...
2.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, et al.
Eur J Cancer
. 2021 Apr;
149:222-232.
PMID: 33872982
Background: Prolgolimab is an IgG1 anti-PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation. We assessed the efficacy and safety of two dosing regimens of prolgolimab...
3.
Ignatova E, Seriak D, Fedyanin M, Tryakin A, Pokataev I, Menshikova S, et al.
Gastric Cancer
. 2020 Jun;
23(6):951-960.
PMID: 32514646
Epstein-Barr virus-associated gastric cancer [EBV-associated GC, EBV( +) GC] is a distinct molecular subtype of gastrointestinal (GI) cancers. It accounts for up to 10% of all molecular subtypes of gastric...
4.
Pokataev I, Kudaibergenova A, Artemyeva A, Popova A, Rumyantsev A, Podluzhny D, et al.
J Gastrointest Cancer
. 2018 Apr;
50(3):478-484.
PMID: 29675723
Background: The aim of our study was to evaluate consistency of SMAD4 expression in different tumor areas and its correlation with recurrence pattern in patients after resection for pancreatic cancer...
5.
Demidova I, Grinevich V, Avdalian A, Imyanitov E, Gikalo M, Savelov N, et al.
Lung Cancer
. 2016 Dec;
103:17-23.
PMID: 28024691
Background: Clinical guidelines highly recommended the detection of potentially targetable genetic aberrations such as anaplastic lymphoma kinase (ALK) rearrangements in patients with non-small cell lung cancer (NSCLC). Few methods, such...
6.
Iveson T, Donehower R, Davidenko I, Tjulandin S, Deptala A, Harrison M, et al.
Lancet Oncol
. 2014 Jun;
15(9):1007-18.
PMID: 24965569
Background: Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human, monoclonal antibody that neutralises HGF. We aimed to assess the safety,...
7.
Fedyanin M, Tryakin A, Mosyakova Y, Pokataev I, Bulanov A, Zakharova T, et al.
J Cancer Res Clin Oncol
. 2013 Dec;
140(2):311-8.
PMID: 24337455
Purpose: Patients (pts) with mediastinal nonseminomatous germ cell tumors (MNGCT) are belonged to poor prognostic group by IGCCCG. We retrospectively studied the prognostic factors and efficacy of different chemotherapeutic regimen...
8.
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al.
Lancet
. 2010 Feb;
375(9712):377-84.
PMID: 20113825
Background: The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 (also known as ERBB2) overexpression or...
9.
Garin A, Manikhas A, Biakhov M, Chezhin M, Ivanchenko T, Krejcy K, et al.
Breast Cancer Res Treat
. 2007 Sep;
110(2):309-15.
PMID: 17851759
Background: Pemetrexed and carboplatin have demonstrated activity in breast cancer. Their potential synergism in experimental models and the proven efficacy of pemetrexed/platinum in other indications make pemetrexed/carboplatin an attractive combination...